跳至主要内容
临床试验/NCT00764270
NCT00764270已完成2 期

The Role of R-alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease

Oregon State University1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2011年8月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
28
试验地点
1
主要终点
hs-CRP

研究概览

简要总结

The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors in people with documented heart disease and increased levels of inflammation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Documented congestive heart disease (CHD)(defined as at least one significant coronary stenosis > 50% on angiography, or history of documented myocardial infarction)
  • •Not diagnosed with unstable angina, uncontrolled hypertension, heart failure, recent myocardial infarction (within last six months)
  • •Not taking insulin or oral hypoglycemic agents, anti-inflammatory drugs other than aspirin, or hormone replacement therapy
  • •On stable doses for four weeks prior to entry of lipid-lowering therapy (statins), aspirin, and angiotensin-converting enzyme inhibitors or other blood pressure medications. P
  • •No tobacco use within 3 months of the study
  • •No laboratory evidence of renal, hepatic, or hematological abnormalities
  • •Not currently taking vitamin or antioxidant supplements, including R-alpha lipoic acid, except standard multivitamin/mineral supplements containing not more than the Daily Value (DV) of the vitamins and minerals;
  • •Elevated levels of urinary and plasma F2-isoprostanes
  • •Elevated plasma levels of hs-CRP

排除标准

  • 未提供

研究组 & 干预措施

Lipoic acid treatment

Active Comparator

Participants take lipoic acid with a washout period before or after placebo.

干预措施: R-alpha lipoic acid (Dietary Supplement)

Placebo treatment

Placebo Comparator

Participants take placebo with a washout period before or after lipoic acid treatment

干预措施: R-alpha lipoic acid (Dietary Supplement)

结局指标

主要结局

hs-CRP

时间窗: 12,20 & 32 weeks

High sensitive C-reactive protein

次要结局

  • 8-lso-PGF2a(12, 20 & 32 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gerd Bobe

Principal Investigator, Linus Pauling Institute Associate Professor, Department of Animal and Rangeland Sciences

Oregon State University

研究点 (1)

Loading locations...

相似试验